Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: PR Newswire
– 12% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 13% year-over-year –– Submitted zanidatamab BLA for 2L BTC; expect to launch in 2025 or earlier –– Top-line Phase 2b data from suvecaltamide trial in essential tremor expected in late 1H24 –– 2024 total revenue guidance affirmed at $4.0 to $4.2 billion –DUBLIN, May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024."In the first quarter of 2024, we delivered combined double-digit year-over-year growth from our key growth drivers: Xywav, Epidiolex and Rylaze. We also significantly advanced our zanidatamab program with the completion of the BLA for 2L BTC," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "We believe the robust growth in patients benefitting from Xywav underscores the appreciation physicians and patients h
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Groundbreaking Data Collection Platform opens to accelerate research in Central Disorders of Hypersomnolence [Yahoo! Finance]Yahoo! Finance
- Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA [Seeking Alpha]Seeking Alpha
- Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases [Yahoo! Finance]Yahoo! Finance
- Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug [Seeking Alpha]Seeking Alpha
- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 5/1/24 - Miss
JAZZ
Sec Filings
- 5/7/24 - Form 4
- 5/3/24 - Form 144
- 5/2/24 - Form 10-Q
- JAZZ's page on the SEC website